View : 165 Download: 30

Full metadata record

DC Field Value Language
dc.contributor.author서은경*
dc.contributor.author윤이수*
dc.date.accessioned2024-02-06T16:31:15Z-
dc.date.available2024-02-06T16:31:15Z-
dc.date.issued2023*
dc.identifier.issn1424-8247*
dc.identifier.otherOAK-34527*
dc.identifier.urihttps://dspace.ewha.ac.kr/handle/2015.oak/267044-
dc.description.abstractPerilla frutense var. acuta (Lamiaceae) has been used to treat indigestion, asthma, and allergies in traditional medicine. In this study, luteolin 7-O-diglucuronide (1), apigenin 7-O-diglucuronide (2), and rosmarinic acid (3) were isolated from the leaves of P. frutescens var. acuta through various chromatographic purification techniques. Several approaches were used to investigate the anti-inflammatory activity of the constituents (1–3) and their working mechanisms. In silico docking simulation demonstrated that 1–3 would work as a PPAR-α/δ/γ agonist, and in vitro PPAR-α/δ/γ transcriptional assay showed that the Perilla water extract (PWE) and 3 increased PPAR-α luciferase activity (1.71 and 1.61 times of the control (PPAR-α + PPRE, p < 0.001)). In the NF-κB luciferase assay, 1 suppressed NF-κB activity the most (56.83% at 5 µM; 74.96% at 10 µM; 79.86% at 50 µM). In addition, 1 and 2 inhibited the mRNA expression of NF-κB target genes, including Il6, Mcp1, and Tnfa, at 50 µM, and 3 suppressed the genes at the mRNA level in a dose-dependent manner. We report that 1 and 2 exert anti-inflammatory effects through NF-κB inhibition, and the PPAR-α/NF-κB signaling pathway is related to the anti-inflammatory activity of 3. © 2023 by the authors.*
dc.languageEnglish*
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)*
dc.subjectanti-inflammation*
dc.subjectflavonoid diglucuronide*
dc.subjectnuclear factor kappa B*
dc.subjectPerilla frutescens var. acuta*
dc.subjectperoxisome proliferator-activated receptor*
dc.titleAnti-Inflammatory Activity of the Constituents from the Leaves of Perilla frutescens var. acuta*
dc.typeArticle*
dc.relation.issue12*
dc.relation.volume16*
dc.relation.indexSCIE*
dc.relation.indexSCOPUS*
dc.relation.journaltitlePharmaceuticals*
dc.identifier.doi10.3390/ph16121655*
dc.identifier.wosidWOS:001132186600001*
dc.identifier.scopusid2-s2.0-85180710272*
dc.author.googleYoun*
dc.author.googleIsoo*
dc.author.googleHan*
dc.author.googleSujin*
dc.author.googleJung*
dc.author.googleHee Jin*
dc.author.googleNoh*
dc.author.googleSang Gyun*
dc.author.googleChung*
dc.author.googleHae Young*
dc.author.googleKoo*
dc.author.googleYean Kyoung*
dc.author.googleShin*
dc.author.googleSunhye*
dc.author.googleSeo*
dc.author.googleEun Kyoung*
dc.contributor.scopusid서은경(7005953758)*
dc.contributor.scopusid윤이수(55699411900)*
dc.date.modifydate20240426112550*


qrcode

BROWSE